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Abstract: Esophageal cancer (EC) is one of the most aggressive malignant tumors of the gastrointestinal tract.
There are two distinct histological types of EC: esophageal squamous cell carcinoma and adenocarcinoma of the
esophagus. Etiologic factors and the patterns of incidence of both subtypes are different. Matrix metalloprotein-
ases (MMPs) and their tissue inhibitors (TIMPs) play an important role in esophageal carcinogenesis. Gellati-
nases MMP-2 and MMP-9 are able to degrade collagen IV from basement membranes and extracellular matrix
which is related to tumor progression, including invasion, metastasis, growth and angiogenesis. It has been
shown that increased expression of MMPs plays a crucial role in the development of several human malignan-
cies, including esophageal cancer. The activity of MMPs is regulated by their endogenous natural inhibitors
(TIMPs). Among these, the roles of TIMP-1 and TIMP-2 in EC development, tumor progression and formation
of metastases have been most extensively characterized and best recognized. (Folia Histochemica et Cytobiolog-
ica 2012, Vol. 50, No. 1, 12–19)
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Esophageal cancer — epidemiology
and risk factors
Esophageal cancer (EC) belongs to the most aggressive
malignant tumors of the alimentary tract. The frequen-
cy of new cases of EC in Western Europe and the USA
is still increasing [1, 2]. It is the eighth most frequent
tumor disease and the sixth leading cause of cancer death
worldwide [3]. It has been established that the rates of
mortality and incidence of EC are quite similar — prob-
ably because of the relatively late stage of diagnosis and
the rapid progression of the tumor [4, 5]. The occur-
rence of this tumor increases with age. The highest inci-
dence of EC is observed in the age group between 50
and 70 years. In addition, EC relates to gender and is
diagnosed more frequently in males than in females, with
an approximate ratio 3–5:1 [6].
EC is characterized by rapid development in most
cases. The prognosis in esophageal cancer is generally
poor, even though the tumor is surgically removed at
its early, resectable stage. Five-year survival of patients
with EC is less than 5% [7]. Moreover, only 10–20% of
patients who undergo radical esophagectomy survive
five years. In patients with an inoperable cancer, the
median survival is estimated as 13–29 months [7].
There are two distinct histological types of EC: esoph-
ageal squamous cell carcinoma (ESCC) and adenocar-
cinoma of the esophagus (ACE); the etiologic factors
and the patterns of their incidence are different [8]. The
most frequent histological type is squamous cell carci-
noma, although in last decades the worldwide propor-
tion of adenocarcinomas has increased almost five-fold
[8]. Moreover, in Western Europe and the USA, the
percentage of ACE among all cases of EC reaches 50%
[1]. It has been shown that in the United States, the in-
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cidence of ESCC has decreased by about 30% in last 30
years, and the greatest decline was observed in black
males [8]. On the other hand, the frequency of ACE has
increased four-fold in the same period, with a nearly
five-fold elevation among white males [8].
Moreover, the established risk factors for EC are
different in each type of tumor. Dietary factors influ-
ence both types of EC, and a higher intake of fruit
and vegetables is associated with a reduced incidence
of tumor [8]. Increased body mass index (BMI) is
strongly associated with ACE risk, whereas obesity
or overweight shows no association, or an inverse re-
lationship, with ESCC [8, 9]. Lower socioeconomic
status, associated with malnutrition, insufficient vita-
min intake, smoking, and alcohol abuse, significantly
increases the incidence of ESCC [8, 10]. Additionally,
in case-control studies, the independent and synergis-
tic effect of smoking and alcohol has been shown [1].
ACE is more frequent in white males from higher
socioeconomic groups. In addition, gastroesophageal
reflux disease is consistently associated with ACE [9].
Pathogenesis of this type of cancer leads from chron-
ic reflux to esophagitis and metaplastic lesions in Bar-
rett’s esophagus (BE), which might result in the de-
velopment of adenocarcinoma [11, 12].
Moreover, certain infectious agents, such as human
papilloma virus (HPV), herpes simplex virus (HSV)
and Epstein–Barr virus (EBV) might be risk factors
for esophageal cancer [13, 14]. The presence of HPV
has been found in 20–70% of EC patients [15].
Esophageal cancer is a very difficult malignancy to
cure and still has a poor prognosis. Reasons include late
diagnosis of the tumor, biological features of the tumor,
and a lack of early symptoms. The main method of tu-
mor recognition in the esophagus is endoscopic exami-
nation and histopathological assessment of material
obtained during biopsy. Moreover, endoscopy allows the
detection of premalignant lesions and the early stage of
EC. Unfortunately, there are no suitable serum/plasma
biomarkers of EC, which would allow for the detection
of this malignancy and its screening, especially compared
to other tumors of the gastrointestinal tract. Some tu-
mor markers have been tested for their usefulness in
primary diagnostics of EC patients, estimating progno-
sis, monitoring of therapy and early detection of tumor
recurrence. Squamous cell cancer antigen (SCC–Ag)
and carcinoembryonic antigen (CEA) are the tumor
markers commonly used in the diagnostics of esophageal
cancer, but their diagnostic sensitivity and specificity
remain unsatisfactory [16, 17].
Matrix metalloproteinases (MMPs)
The development of malignant neoplasms is a long-term
and multi-step process, which results in rapid growth
and invasion of tumor cells into lymphatic and blood
vessels [18]. The first step of tumor development and
metastasis is the proteolysis of microvessel basement
membranes and invasion of endothelium. The migra-
tion of tumor cells is associated with the degradation of
the extracellular matrix (ECM) [19]. The ECM is a dy-
namic structure composed of various macromolecules
such as collagen, fibronectin, laminin and proteoglycans
of connective tissue. Their role is the regulation of cells
functions and establishment of a specific microenviron-
ment. Transformation of ECM is an essential factor for
various physiological and pathological processes, tissue
development and formation, proliferation and differ-
entiation of cells, as well as invasion and metastasizing
of neoplastic cells. Moreover, ECM remodeling is a reg-
ulator of stromal-epithelial interactions during carcino-
genesis of malignant tumors [20, 21].
The components of the extracellular matrix (col-
lagen, elastin, and gelatin) are degraded by various
proteolytic enzymes, including matrix metalloprotein-
ases (MMPs). The MMP family includes at least 28
members, representing a large class of multi-domain,
zinc-dependent endopeptidases. All MMPs share
homologous amino acid (AA) sequences, with con-
served specific domain structures, related to their
substrate specificity [22]. The structure of most MMPs
includes a propeptide of about 80 AA, a catalytic do-
main containing about 170 AA, followed by a linker
peptide called the ‘hinge region’, of variable length,
and a hemopexin domain with about 200 AA. Matril-
ysin 1 (MMP-7), matrilysin 2 (MMP-26) and MMP-23
are exceptions, because their molecules lack the link-
er peptide and the hemopexin domain. Moreover,
MMP-23 has a unique C-terminal cysteine-rich do-
main and an immunoglobulin-like domain directly
after the C-terminus of the catalytic domain.
The criterion for membership of the MMP family is
the homology of MMP sequence with the catalytic do-
main of collagenase 1 (MMP-1). There are six main fam-
ilies of MMPs: collagenases (MMP-1, MMP-8 and
MMP-13), gelatinases (MMP-2 and MMP-9), stromel-
ysins (MMP-3, MMP-10 and MMP-11), matrilysins
(MMP-7 and MMP-26), membrane-type MMPs
(MT-MMPs: MMP-14, -15, -16, -17, -24 and -25), and oth-
er MMPs, which are not categorized in any of the previous
groups (MMP-12, -19, -20, -21, -23, -27 and -28) (Table 1).
The MMP may act either as free, unbound secret-
ed enzymes or as transmembrane proenzymes that re-
quire activation after their secretion. The members of
the MMP family form a cascade and activate each oth-
er. Accelerated breakdown of ECM occurs in various
pathological processes, including inflammation, chron-
ic degenerative diseases and tumor invasion. The main
roles of MMPs in pathology include tissue destruction,
fibrosis or may be expressed as weakening of ECM.
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For example, destruction of tissues is observed in can-
cer invasion and metastasis [22], rheumatoid arthritis
and osteoarthritis [23, 24], formation of decubitus and
various ulcers [25], periodontal disease, brain injury
[26] and neuroinflammatory diseases [27]. Fibrosis of
tissues is characteristic for liver cirrhosis, fibrotic lung
disease, otosclerosis, atherosclerosis, and multiple scle-
rosis [28]. The weakening of ECM occurs in dilated
cardiomyopathy, epidermolysis bullosa, aortic aneu-
rysm [29] or restenotic lesions [30].
Tissue inhibitors of
matrix metalloproteinases (TIMPs)
The expression of MMPs is regulated at the transcrip-
tional level by cytokines and growth factors and its
activity could be regulated by proenzyme activation
after its secretion or inhibited by their endogenous
natural inhibitors. The tissue inhibitors of matrix
metalloproteinases (TIMPs) provide a negative con-
trol of MMPs activity. Four various inhibitors of met-
alloproteinases have been characterized so far, des-
ignated as TIMP-1, TIMP-2, TIMP-3, and TIMP-4.
Among them, TIMP-1 and TIMP-2 have been char-
acterized most extensively.
The TIMPs inhibit active MMPs by forming 1:1
stoichiometric non-covalent complexes with the en-
dopeptidase [31]. TIMP-1 and TIMP-2 are capable
of inhibiting the activities of all known MMPs except
MT-MMPs, and play a key role in maintaining the
balance between ECM deposition and degradation
in different physiological processes. Moreover, TIMP-1
can also complex with the precursor of MMP-9 [32],
whereas TIMP-2 and 4 can bind to the zymogen form
Table 1. Classification and functions of matrix metalloproteinases (MMPs)
Group Metalloproteinase Substrates
Matrilysins
The smallest among MMPs, MMP-7 (matrilysin, Collagen type IV, glycoproteins, gelatine
lack of hemopexin domain  metalloendopeptidase)
Collagenases
Contain hemopexin domain MMP-1 (interstitial Collagen type I, II, III, V, VII, VIII, X,
and peptide linking with catalytic collagenase; collagenase 1) gelatine, IL-1b, MMP-2, MMP-9, fibronectin





Metalloproteinases of stroma MMP-3 (stromelysin 1) Proteoglycanes, fibronectin, laminin, elastine,
MMP-10 (stromelysin 2) gelatine, vitronectine, plasminogen, fibrinogen,
MMP-11 (stromelysin 3) fibrine, collagen type III, IV, V, antithrombin III,
MMP-18 (collagenase 4) MMP-1, MMP-2, MMP-8, MMP-9, MMP-13
Gellatinases
High substrate specificity MMP-2 (gelatinase A; Collagen type I, IV, V, VII, X, gelatine, elastine,
to denatured collagen and gelatine 72 KDa metalloproteinase) laminin
MMP-9 (gelatinase B; 92 KDa
metalloproteinase)
Membane-type MMPs
(A) transmembrane-type MMPs MMP-14 (MT1-MMP) Collagen type I, II, III, gelatine, elastine,
MMP-15 (MT2-MMP) laminin, fibronectin, fibrine, proMMP-2, -13
MMP-16 (MT3-MMP)
MMP-24 (MT5-MMP)
(B) GPI-anchored MMPs MMP-17 (MT4-MMP)
MMP-25 (MT6-MMP)
Others MMPs
MMPs which are not categorized MMP-11 (stromelysin) Amelagenine, agrecanes, elastine
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of MMP-2, a 92-kDa type IV procollagenase [33, 34].
TIMP-3 inhibits not only the activity of MPP-1, -2, -3,
-9 and -13 [35], but also the activity of MT-MMPs as
well as TNF-alpha converting enzyme. This inhibitor
is the only member of the TIMP family which is found
exclusively in the extracellular matrix (ECM). How-
ever, the role of TIMPs is not restricted to the inhibi-
tion of MMPs. They possess growth promoting activ-
ities for various cell types as well as having antiangio-
genic properties and promoting apoptosis [36–38].
The role of MMPs and TIMPs
in esophageal cancer
MMP-9
Matrix metalloproteinases, especially MMP-2 and
MMP-9, as well as their inhibitors, TIMP-1 and TIMP-2,
play an important role in tumor invasion and metasta-
sis. The imbalance between MMPs and their inhibi-
tors may facilitate tumor progression. The gellatinas-
es MMP-2 and MMP-9 have been studied in this
regard because of their specificity for breaking down
the collagen of basement membranes [39]. It has been
proved that these enzymes are involved in the devel-
opment of many malignant neoplasms: gastric, col-
orectal, pancreatic and breast cancer [40–43].
High MMP-9 protein expression in tumor tissues
of EC patients has been shown in several studies [4,
18, 44–47]. Percentages of MMP-9 positive immun-
ostaining (diagnostic sensitivity) in esophageal can-
cer tissue reached 78% in the study by Murray et al.
[44] and increased with tumor stage. The diagnostic
sensitivity of MMP-9 immunostaining in the study of
El-Shahat et al. was 100% in stage IV EC [4].
MMP-9 immunohistochemical expression in EC
tissue correlated significantly with the depth of tu-
mor invasion (T factor), lymphatic vessel permeation,
nodal metastases (M factor) and differentiation grade
(4, 19, and 45). In addition, the study of Koyama et
al. demonstrated strong MMP-9 gelatinolytic activity
measured in situ within the tumor nests in EC tissues
[48]. They also demonstrated significant correlation
between vascular invasion and activation of MMP-9
[48]. This is in line with the study of El-Sahat et al.,
who revealed that tissue expression of MMP-9 in EC
tumor samples significantly correlated with the pres-
ence of CD34 antigen (the biomarker of vascular en-
dothelial cells and neoangiogenesis) [4]. Microvessel
density in patients with highly positive staining for
MMP-9 was higher than in those with negative or weak
staining for MMP-9 [4], which suggests that the ex-
pression of MMP-9 possibly could offer additional
information about the aggressiveness and activity of
esophageal carcinoma lesions. Moreover, high expres-
sion of MMP-9 in cancer tissue may be a negative
prognostic factor of EC patients’ survival [45].
The recent study of our research team has shown
that the preoperative serum levels of MMP-9 in esoph-
ageal cancer patients were statistically higher than in
healthy subjects, and correlated with clinical stage of
disease as well as with tumor size [46] (Figure 1). The
diagnostic sensitivity of serum MMP-9 measurement
was higher (70%) than for classical tumor markers
(CEA — 17% and SCC-Ag — 64%) and increased in
the combination of MMP-9 with SCC-Ag [46].
MMP-2
MMP-2 activity in ESCC tissue was significantly in-
creased in comparison with normal esophageal mu-
cosa [49]. Enhanced expression of MMP-2 protein in
ESCC tissues suggests its association with esophageal
tumorigenesis. Overexpression of MMP-2 in ESCC
was found twice as often as in paired distal normal
esophageal tissues [50]. Moreover, MMP-2 might act
as a biomarker of ESCC invasion and lymph node
metastasis in this type of tumor [50]. The overexpres-
sion of MMP-2 in ESCC tumor samples was signifi-
cantly associated with cancer stage, depth of tumor
invasion and presence of lymph node metastases [50].
Additionally, Koyama et al. have also demonstrated
a significant correlation between lymph node metasta-
sis, lymphatic vessels involvement, vascular invasion
and activation of MMP-2 in ESCC tissue using ge-
latine zymography in situ [48].
The expression of MMP-2 might be significantly
associated with the tumor invasion not only in ESCC
cells, but also within normal esophageal tissue sur-
rounding tumor nests. The immunohistochemical anal-
ysis of its expression in relation to clinicopathological
features of esophageal cancer in the study of Ishibashi
et al. revealed that the presence of MMP-2 within can-
cerous lesions was associated with invasion into lym-
phatic and blood vessels [51]. In contrast, expression
of this enzyme within the normal esophageal tissue
around cancerous lesions correlated with depth of tu-
mor infiltration (T factor) and stage of cancer [51].
MMP-2 immunostaining in normal tissue adjacent to
tumor was also a significant prognostic factor of dis-
ease recurrence-free survival in patients with advanced
stages of EC, whereas the presence of this enzyme with-
in ESCC tumor tissue had no significant effect on pa-
tients’ survival, regardless of cancer stage [51].
Other MMPs
Matrix metalloproteinases other than MMP-9 and
MMP-2 might also play a significant role in EC car-
cinogenesis and tumor development. It has been sug-
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gested that MMP-1 was the preinvasive factor in Bar-
rett’s esophagus associated adenocarcinoma of the
esophagus. Esophageal adenocarcinoma is related to
gastroesophageal reflux and Barrett’s esophagus,
which is regarded as a precancerous lesion. Expres-
sion of MMP-1 was found in 95% of cases of ACE
with BE and in 100% of cases of ACE without BE,
whereas no expression of MMP-13 was found in these
specimens [52]. Moreover, increased MMP-1 expres-
sion was observed in tumor cells positive for Ki-67
(the marker of cells’ proliferation) whereas high
MMP-1-mRNA levels were associated with lymph
node metastases [52]. In addition, this enzyme might
be a prognostic factor for EC patients’ survival. The
presence of MMP-1, as investigated by immunohis-
tochemistry on formalin-fixed, wax-embedded sec-
tions of esophageal cancers, was associated with
a particularly poor prognosis and was an independent,
significant prognostic factor [44].
Mukherjee et al. measured protein expression lev-
els of MMP-3 and MMP-10 using gelatin zymogra-
phy in the tumor-associated stroma and tumor epi-
thelium of ESCC [53]. A paired normal esophagus
from a distant site was examined as a control. The
authors found that MMP-3 and MMP-10 were strongly
expressed in all examined tumors with little or no ex-
pression in the normal esophageal tissue [53].
In the study of Chen et al. the membrane-type 2
MMP (MT2-MMP) expression pattern in EC tissues
was investigated and correlated to clinicopathologi-
cal features of tumor, neoangiogenesis and postop-
erative prognoses [54]. They demonstrated that pos-
itive MT2-MMP immunoreactions were found in 85%
of total tumor sections, whereas none or very weak
MT2-MMP staining occurred in normal esophageal
tissues [54]. Moreover, MT2-MMP immunochemical
staining intensity significantly correlated with angio-
genesis in tumor tissue and tumor size [54].
TIMPs
TIMPs inhibit the activity of matrix metalloprotein-
ases, and thus were considered to inhibit carcinoma
invasion and metastasis. An inverse correlation be-
tween expression of TIMP-2 in ESCC cell sub-lines
CE81T/VGH and invasive ability of neoplastic cells
has been demonstrated [55]. The results indicate that
TIMP-2 might have an inhibitory effect on esophageal
tumor development and they are in line with the study
of Sharma et al. who determined the prognostic sig-
nificance of TIMP-1 and TIMP-2 immunostaining in
esophageal squamous cell carcinoma in relation to
tumor progression, invasion and metastasis [56].
In their study, the expression of TIMP-1 was ob-
served in 66% of ESCC cases, whereas TIMP-2 was
observed in 72%, although TIMP-1(+)/TIMP-2(+)
phenotype was inversely correlated with nodal inva-
siveness of the tumor [56]. Additionally, they analyzed
the presence of both MMPs inhibitors in esophageal
dysplastic tissues. An increased expression of TIMP-1
and TIMP-2 was observed in 69% and 50% of esoph-
ageal dysplasias, respectively, which suggests that
these alterations are rather early events in esophageal
tumorigenesis [56]. In addition, it has been shown that
MMP-11(+)/TIMP-2(–) phenotype might be a signif-
icant predictive factor for disease-free survival in
ESCC patients [56]. The survival analysis in their study
showed that patients with TIMP-2-negative carcino-
Figure 1. Typical staining result of MMP-9 in EC cancer cells from our previously published research paper [46]. A–D:
Squamous cell carcinoma. A — intense expression in cancer cells (3 pts); B — moderate expression in cancer cells (2 pts);
C — weak expression in cancer cells (1 pt); D — no expression in cancer cells (0 pt); E–H: Adenocarcinoma. E — intense
expression in cancer cells (3 pts); F — moderate expression in cancer cells (2 pts); G — weak expression in cancer cells
(1 pt); H — no expression in cancer cells (0 pt)
A B C D
E F G H
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ma had a significantly shorter disease-free survival in
comparison with TIMP-2-positive tumors [56]. More-
over, these observations are in line with the study of
Vegh et al., who found that the expression of TIMP-1
in ACE samples from EC patients with more than
three positive lymph nodes was significantly lower
than in subjects without lymph node involvement [57].
On the other hand, the obtained data is in opposition
to the study of Mori et al. [58], who compared expression
of TIMP-1 mRNA in tumoral (T) and corresponding
normal (N) tissues of EC and evaluated the T:N ratio of
TIMP-1 mRNA expression in each case [58]. A signifi-
cantly higher frequency of lymphatic and vascular inva-
sion, lymph node metastasis and advanced-stage disease,
as well as poorer prognosis, was observed in high-expres-
sion cases (T:N > 2.0) than in the low-expression group
(T:N £ 2.0) [58]. Moreover, in multivariate analysis,
TIMP-1 expression status was an independent factor for
EC patients’ prognosis [58]. They suggested that
TIMP-1 expression correlated with tumor extension
of esophageal carcinoma [58].
In the study of Salmela et al. it was demonstrated
that in esophageal adenocarcinoma, TIMP-1 was ex-
pressed in 80% of cases, whereas TIMP-3 was ex-
pressed in 73% of ACE tissue [59]. In contrast to TIMP-1,
which was expressed in deeper areas of lesions, TIMP-3
was present throughout the cancer tissue, and in larg-
er numbers of cells [59]. Moreover, the expression of
TIMP-1 was observed particularly in aggressive
tumors with poor differentiation, predominantly in fi-
broblast-like cells and in stromal cells surrounding glan-
dular structures in 67% of lymph-node metastases,
Table 2. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in esophageal cancer — summary
Feature tested MMPs TIMPs
Expression in EC – TIMP-2:
cell lines Chen 2010 [55]
Expression MMP-9: TIMP-1:
in EC tissue El-Shahat 2004 [4] Sharma 2004 [56]
Samantaray 2004 [18] Vegh 2007 [57]
Murray 1998 [44] Salmela 2001 [59]
Tanioka 2003 [45] TIMP-2:
Mroczko 2008 [46, 47] Sharma 2004 [56]
MMP-2: TIMP-3:
Augoff 2009 [4] Salmela 2001 [59]












features of tumor El-Shahat 2004 [4] Vegh 2007 [57]
Gu 2005 [19] Salmela 2001 [59]
Tanioka 2003 [45] TIMP-1:
MMP-2: Mori 2000 [58]
Li 2009 [50] TIMP-3:
Ishibashi 2004 [51] Salmela 2001 [59]
MT-2 MMP: Miyazaki 2004 [60]
Chen 2010 [54]
Enzymatic activity MMP-9: –




Ishibashi 2004 [51] Mori 2000 [58]
Serum/plasma levels MMP-9: –
Mroczko 2008 [46]
Prognostic factor of MMP-9: TIMP-1:
overall or disease- Tanioka 2003 [45] Mori 2000 [58]
-free survival MMP-2: TIMP-2:
Murray 1998 [44] Sharma 2004 [56]
MT-2 MMP: TIMP-3:
Chen 2010 [54] Miyazaki 2004 [60]
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whereas expression of TIMP-3 was detected in 83% of
samples of intestinal metaplasia and lymph node me-
tastases [59]. These observations might reflect differ-
ent biological roles of these two TIMPs; TIMP-1 is
upregulated after the malignant cells protrude into
deeper parts of the esophageal mucosa, whereas TIMP-3
is upregulated earlier in oncogenesis.
Miyazaki et al. analyzed the relationship between
TIMP-3 reduction and clinicopathological factors in
ESCC tumors [60]. They observed significant correla-
tions between TIMP-3 presence in ESCC tumors and
depth of tumor invasion, number of lymph node me-
tastases, infiltrative growth pattern and cancer stage
[60], which suggests that decreased expression of TIMP-3
is related to invasive activity and metastasis in this type
of EC [60]. In addition, the survival rates of patients
with TIMP-3(–) cancer were significantly lower than
those of patients with TIMP-3(+) tumors, making the
prognosis for patients with cancer that has lost TIMP-3
significantly less favorable than that for patients with
cancer that has maintained TIMP-3 [60].
Conclusions
Esophageal cancer is one of the most aggressive ma-
lignant tumors of the upper gastrointestinal tract.
There are two distinct types of this tumor: adenocar-
cinoma of the esophagus and esophageal squamous
cell carcinoma, which differ in their etiology, risk fac-
tors, and incidence.
Matrix metalloproteinases and their tissue inhibi-
tors are now recognized as important factors in the
development of both types of esophageal cancer.
MMPs, especially gellatinases A and B (MMP-2 and
MMP-9, respectively), might facilitate tumor invasion
and metastases. The effects of TIMPs on esophageal
tumorigenesis are multifunctional and paradoxical —
they are considered as inhibitors of tumor development
as well as growth factors (Table 2). The negative prog-
nostic factors of EC patients’ survival were: high ex-
pression of MMP-9 and MMP-1 in cancer cells, increase
in MMP-2 immunoreactivity in normal tissue adjacent
to tumor, as well as the increased ratio between the
expression of TIMP-1 in tumoral tissue of EC and in
corresponding normal cells. In contrast, the absence
of the expression of TIMP-2 or TIMP-3 in cancer cells
was an unfavorable prognostic factor in EC patients.
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